setmelanotide (Imcivree) Report issue

Biologics Peptide Orphan Drug FDA Approved FDA First in Class Breakthrough Therapy FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Setmelanotide, sold under the brand name Imcivree, is a medication used for the treatment of genetic obesity caused by a rare single-gene mutation.   Wikipedia

Chemistry

  • SMILES: CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](C)NC1=O
  • InChIKey: HDHDTKMUACZDAA-PHNIDTBTSA-N
  • Mol. Mass: 1117.33
  • ALogP: Missing data
  • ChEMBL Molecules:
    setmelanotide  
    setmelanotide acetate  
More Chemistry

Pharmacology

Alternative names

bim-22493 | rm-493 | setmelanotide

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (1)


 

Obesity (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Alstrom Syndrome (Phase 3)

Bardet-Biedl Syndrome (Phase 3)

Healthy Volunteers (Phase 4)

Melanocortins (Phase 3)

Mutation (Phase 2)

Obesity (Phase 3)

Obesity, Morbid (Phase 1)

Overweight (Phase 2)

Prader-Willi Syndrome (Phase 2)

Renal Insufficiency (Phase 1)

Smith-Magenis Syndrome (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue